|1.||Lane, Hsien-Yuan: 2 articles (05/2014 - 12/2013)|
|2.||Tsai, Guochuan E: 2 articles (05/2014 - 12/2013)|
|3.||Shih, Huei-Chuan: 2 articles (07/2008 - 12/2006)|
|4.||Lin, Chih-Lung: 2 articles (07/2008 - 12/2006)|
|5.||Lundqvist, Hans: 2 articles (07/2006 - 11/2004)|
|6.||Orlova, Anna: 2 articles (07/2006 - 11/2004)|
|7.||Tolmachev, Vladimir: 2 articles (07/2006 - 11/2004)|
|8.||Roussakis, Christos: 2 articles (08/2004 - 08/2003)|
|9.||Jacquot, Catherine: 2 articles (08/2004 - 08/2003)|
|10.||Tomasoni, Christophe: 2 articles (08/2004 - 08/2003)|
|1.||Body Weight (Weight, Body)
07/01/2002 - "The estimated intakes of benzoates and sorbates for the average consumer were below the ADIs, ranging from 0.3 to 0.9 and 0.2 to 0.3 mg kg(-1) body weight, respectively. "
11/01/2001 - "To test the role of gene expression of the classical ER (ER alpha) in the inhibitory effects of E on food intake and body weight, we ovariectomized and administered E2 benzoate (75 pg/d) or vehicle to wild-type (WT) mice and mice with a null mutation of ER alpha (alpha ERKO). "
02/01/1978 - "Replacement therapy with estradioal benzoate reduced the body weight and food intake of ovariectomized animals relative to oil-injected, ovariectomized control animals. "
04/01/1992 - "Benzoate-metabolizing capacity was studied in control subjects and in liver disease patients after intra-venous loading of 15 mg benzoate per kg of body weight. "
11/01/1984 - "For Exp. 1, oestradiol benzoate doses were 4, 16 and 64 micrograms/kg body weight; since highest mean LH peaks followed use of the 16 micrograms/kg dose, this treatment was used in later studies. "
10/01/1993 - "An introduction to contemporary efforts at employing benzoate to treat hyperammonemia is followed by a detailed review of studies on benzoate metabolism and resultant toxic interactions with other major metabolic pathways. "
04/01/1987 - "Nonlinear elimination of benzoate in patients with congenital hyperammonemia."
01/01/1989 - "Recently it has been advocated that benzoate is effective to prevent hyperammonemia in patients with OTC deficiency. "
04/01/1990 - "These results demonstrate the individual effects of hyperammonemia and benzoate therapy on carnitine metabolism, which may be helpful in understanding and ameliorating the therapeutic approach to hereditary hyperammonemias."
11/01/1989 - "The cumulative effect of benzoate conjugation to drain these ammoniagenic precursors through glycine may be the basis of its therapeutic effect in hyperammonemia."
|3.||Schizophrenia (Dementia Praecox)
12/01/2013 - "Benzoate adjunctive therapy significantly improved a variety of symptom domains and neurocognition in patients with chronic schizophrenia. "
12/01/2013 - "Benzoate produced a 21% improvement in PANSS total score and large effect sizes (range, 1.16-1.69) in the PANSS total and subscales, Scales for the Assessment of Negative Symptoms-20 items, Global Assessment of Function, Quality of Life Scale and Clinical Global Impression and improvement in the neurocognition subtests as recommended by the National Institute of Mental Health's Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative, including the domains of processing speed and visual learning. "
10/01/1960 - "[The importance of the Quick benzoate tolerance test in schizophrenia]."
12/01/2013 - "Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor."
01/01/2015 - "In this study, we have examined the efficacy of PHD inhibitor ethyl 3,4-dihydroxy benzoate (EDHB) in affording protection against hypoxia-induced oxidative damage in L6 myoblast cells. "
01/01/2015 - "Ethyl 3,4-dihydroxy benzoate, a unique preconditioning agent for alleviating hypoxia-mediated oxidative damage in L6 myoblasts cells."
05/01/2010 - "palustris in response to anoxia and the presence of benzoate and/or benzoyl-CoA (Bz-CoA). "
06/01/1986 - "The effectiveness of benzoate in the management of seizures in nonketotic hyperglycinemia."
04/01/1998 - "We administered benzoate (at doses of 500 to 750 mg/kg/day) and dextromethorphan (at doses of 3.5 to 22.5 mg/kg/day) to four infants with nonketotic hyperglycinemia with follow-up of 3 months to 6 years. "
04/01/1998 - "Long-term use of high-dose benzoate and dextromethorphan for the treatment of nonketotic hyperglycinemia."
12/04/1995 - "Benzoate therapy and carnitine deficiency in non-ketotic hyperglycinemia."
07/01/1992 - "Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant."
|4.||Heterologous Transplantation (Xenotransplantation)